2026-08-19T09:28:07Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/88112024-03-13T01:05:27Zcom_10259_4219com_10259_5086com_10259_2604col_10259_4220

Santos García, Diego Naya Ríos, Lucía Deus-Fonticoba, Teresa de Cores Bartolomé, Carlos García Roca, Lucía Feal Painceiras, María Martínez Miró, Cristina Canfield, Héctor Jesús, Silvia Aguilar, Miquel Pastor, Pau Cosgaya, Marina García Caldentey, Juan Caballol, Núria Legarda, Inés Hernández Vara, Jorge Cabo López, Iria López Manzanares, Lydia González Aramburu, Isabel Ávila Rivera, María A. Gómez Mayordomo, Víctor Nogueira, Víctor Puente, Víctor Dotor, Julio Borrue, Carmen Solano Vila, Berta Álvarez Saúco, María Vela Desojo, Lydia Escalante Arroyo, Sonia Cubo Delgado, Esther Carrillo Padilla, Francisco Martínez Castrillo, Juan Carlos Sánchez Alonso, Pilar Alonso Losada, María Gema López Ariztegui, Nuria Gastón, Itziar Kulisevsky Bojarsky, Jaume Blázquez Estrada, Marta Seijo, Manuel Ruíz Martínez, Javier Valero, Caridad Kurtis, Mónica M. Fabregues, Oriol de González Ardura, Jessica Alonso Redondo, Rubén Ordás Bandera, Carlos Manuel López Díaz, Luis M. McAfee, Darrian Martínez Martín, Pablo Mir, Pablo 2024-03-12T13:10:09Z 2024-03-12T13:10:09Z 2021-12 http://hdl.handle.net/10259/8811 10.3390/diagnostics11122380 2075-4418 Background and objective: Diplopia is relatively common in Parkinson’s disease (PD) but is still understudied. Our aim was to analyze the frequency of diplopia in PD patients from a multicenter Spanish cohort, to compare the frequency with a control group, and to identify factors associated with it. Patients and Methods: PD patients who were recruited from January 2016 to November 2017 (baseline visit; V0) and evaluated again at a 2-year ± 30 days follow-up (V2) from 35 centers of Spain from the COPPADIS cohort were included in this longitudinal prospective study. The patients and controls were classified as “with diplopia” or “without diplopia” according to item 15 of the Non-Motor Symptoms Scale (NMSS) at V0, V1 (1-year ± 15 days), and V2 for the patients and at V0 and V2 for the controls. Results: The frequency of diplopia in the PD patients was 13.6% (94/691) at V0 (1.9% in controls [4/206]; p < 0.0001), 14.2% (86/604) at V1, and 17.1% (86/502) at V2 (0.8% in controls [1/124]; p < 0.0001), with a period prevalence of 24.9% (120/481). Visual hallucinations at any visit from V0 to V2 (OR = 2.264; 95%CI, 1.269–4.039; p = 0.006), a higher score on the NMSS at V0 (OR = 1.009; 95%CI, 1.012–1.024; p = 0.015), and a greater increase from V0 to V2 on the Unified Parkinson’s Disease Rating Scale–III (OR = 1.039; 95%CI, 1.023–1.083; p < 0.0001) and Neuropsychiatric Inventory (OR = 1.028; 95%CI, 1.001–1.057; p = 0.049) scores were independent factors associated with diplopia (R2 = 0.25; Hosmer and Lemeshow test, p = 0.716). Conclusions: Diplopia represents a frequent symptom in PD patients and is associated with motor and non-motor severity. application/pdf eng MDPI Diagnostics. 2021, V. 11, n. 2, 2380 https://doi.org/10.3390/diagnostics11122380 Atribución 4.0 Internacional http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Changes Motor Parkinson’s disease Phenotype PIGD Tremor Sistema nervioso-Enfermedades Medicina Neurología Nervous system-Diseases Medicine Neurology Diplopia Is Frequent and Associated with Motor and Non-Motor Severity in Parkinson’s Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up info:eu-repo/semantics/article info:eu-repo/semantics/acceptedVersion Diagnostics 11 12